摘要
目的探讨华蟾素片联合SOX方案(奥沙利铂+替吉奥)治疗晚期胃癌的临床疗效。方法选取2015年1月—2017年12月涟水县人民医院收治的60例晚期胃癌患者作为研究对象,根据不同的治疗方式将患者分为对照组和治疗组,每组各30例。对照组患者采用SOX方案治疗:静滴注射用奥沙利铂130 mg/(m^2·d),用10%葡萄糖注射液500 mL稀释后静滴3 h,21 d给药1次;同时餐后用温水送服替吉奥胶囊,80 mg/(m^2·d),2次/d,连续14 d,停药7 d。治疗组在对照组基础上口服华蟾素片,3片/次,3次/d。21 d为1个周期,两组患者均进行2个周期的治疗。观察两组患者的临床疗效,同时比较两组治疗前后的血清肿瘤指标水平、疼痛评分(VAS)和生活质量综合评定问卷评分。结果治疗后,治疗组的总有效率(RR)和肿瘤控制率(DCR)分别为63.3%、83.3%,均明显高于对照组的36.7%、60.0%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者的癌胚抗原(CEA)和糖类抗原19-9(CA19-9)水平均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05),且治疗后治疗组血清肿瘤指标均明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者VAS评分均明显降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组的VAS评分明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者的社会功能、心理功能、功能和物质生活评分均明显提高,同组治疗前后比较差异具有统计学意义(P<0.05),且治疗后治疗组生活质量水平显著高于对照组,两组比较差异具有统计学意义(P<0.05)。结论华蟾素片联合SOX化疗方案治疗晚期胃癌具有较好的临床疗效,在不增加化疗副反应的情况下,可有效缓解患者的癌性疼痛状况并可改善患者的预后,值得临床推广应用。
Objective To investigate the clinical efficacy of Huachansu Tablets combined with SOX regimen(oxaliplatin + tegafur) in treatment of advanced gastric cancer. Methods Patients(30 cases) with advanced gastric cancer in Lianshui County People’s Hospital from January 2015 to December 2017 were divided into control and treatment groups according to different treatment methods, and each group had 30 cases. Patients in the control group were given SOX regimen, iv administer with Oxaliplatin for injection, 130 mg/(m^2·d), diluted with 10% glucose injection 500 mL for 3 h, 1 time/21 d. At the same time, Tegafur, Gimeracil and Oteracil Potassium Capsules were given with warm water after meals, 80 mg/(m^2·d), twice daily, treated for 14 d withdrawal for 7 d. Patients in the treatment group were po administered with Huachansu Tablets on the basis of the control group, 3 tablets/time, three times daily.A course had 21 d, and patients in two groups were treated for 2 courses. After treatment, the clinical efficacies were evaluated, the serum tumor indicators, cancer pain scores and Quality of Life Comprehensive Assessment Questionnaire in two groups before and after treatment were compared. Results After treatment, the RR and DCR in the treatment group were 63.3% and 83.3%,respectively, which were significantly higher than 36.7% and 60.0% in the control group, and there were differences between two groups(P < 0.05). After treatment, the levels of CEA and CA19-9 in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05), and serum tumor indicators levels in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the VAS scores in two groups was significantly decreased, and the difference was statistically significant in the same group(P < 0.05), and VAS scores in the treatment group after treatment were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the scores of social function, psychological function, function, and material life scores in two groups were significantly increased, and the difference were statistically significant in the same group(P < 0.05). And qualities of life in the treatment group after treatment were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Huachansu Tablets combined with SOX regimen has a good clinical effect in treatment of advanced gastric cancer can effectively alleviate the patients’ cancer pain, and improve the prognosis of patients without increasing the side effects of chemotherapy, which has a certain clinical application value.
作者
李爱峰
印海林
蔺梅
季言俊
王宝然
LI Ai-feng;YIN Hai-lin;LIN Mei;JI Yan-jun;WANG Bao-ran(Department of Oncology, Lianshui County People's Hospital, Huaian 223400, China)
出处
《现代药物与临床》
CAS
2019年第3期714-718,共5页
Drugs & Clinic
关键词
华蟾素片
SOX方案
注射用奥沙利铂
替吉奥胶囊
晚期胃癌
癌胚抗原
糖类抗原19-9
疼痛评分
生活质量综合评定问卷评分
Huachansu Tablets
SOX regimen
Oxaliplatin for injection
Tegafur,Gimeracil and Oteracil Potassium Capsules
advanced gastric cancer
CEA
CA19-9
cancer pain score
quality of life comprehensive assessment questionnaire
